|0.485|| -0.025 / -4.90%|
ImmunoCellular Therapeutics Ltd. is a clinical-stage biotechnology company that is developing immune-based therapies for the treatment of cancers. Immunotherapy is an emerging approach to treating cancer in which a patients own immune system is stimulated to target tumor antigens, which are molecular signals that the immune system uses to identify foreign bodies. Its cell-based vaccine technologies are primary platform technologies and commercial prospects will be heavily dependent on the outcome of the contemplated clinical trials for current lead vaccine product candidate. Its product pipeline includes peptide based vaccine to target cancer stem cells, cellular immunotherapies to target cancer associated antigens, and monoclonal antibodies to diagnose and treat several different cancers. ImmunoCellular product candidates include ICT-107, CT-121, ICT-109, ICT-037, ICT-69 and CT-Diagnostic-SCLC. Its antibodies are designed to treat small cell lung cancer, pancreatic cancer, multiple myeloma and ovarian cancer. The company was founded by John S. Yu on March 20, 1987 and is headquartered in Woodland Hills, CA.
|John S. Yu||Chairman, Secretary & Chief Scientific Officer|
|Andrew Gengos||President, Chief Executive Officer & Director|
|Steven J. Swanson||Senior Vice President-Research|
|Anthony J. Gringeri||Senior Vice President-Strategic Resources|
|David E. Fractor||Chief Accounting Officer & Vice President-Finance|